1. Home
  2. UPWK vs OMER Comparison

UPWK vs OMER Comparison

Compare UPWK & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Upwork Inc.

UPWK

Upwork Inc.

HOLD

Current Price

$9.10

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$19.17

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UPWK
OMER
Founded
1998
1994
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2018
2008

Fundamental Metrics

Financial Performance
Metric
UPWK
OMER
Price
$9.10
$19.17
Analyst Decision
Hold
Buy
Analyst Count
10
3
Target Price
$9.88
★ $27.50
AVG Volume (30 Days)
★ 2.3M
997.7K
Earning Date
11-02-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 98.15
EPS
0.44
★ 0.77
Revenue
★ $787,784,000.00
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$73.59
P/E Ratio
★ $20.33
$23.21
Revenue Growth
★ 2.40
N/A
52 Week Low
$7.44
$6.24
52 Week High
$22.84
$21.24

Technical Indicators

Market Signals
Indicator
UPWK
OMER
Relative Strength Index (RSI) 57.32 57.03
Support Level $8.29 $18.01
Resistance Level $9.27 $19.81
Average True Range (ATR) 0.33 0.87
MACD 0.06 0.05
Stochastic Oscillator 64.48 69.74

Price Performance

Historical Comparison
UPWK
OMER

About UPWK Upwork Inc.

Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes and connects businesses with AI-enabled talent across every on-demand work type, including freelance, agency, fractional, and payrolled. The business generates revenue from Talent and Clients across the USA, India, Pakistan, the Philippines and the rest of the world. Maximum revenue of the company is derived from Talent segment.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: